ProShares Ultra Nasdaq Biotechnology (NASDAQ:BIB – Get Free Report) was the target of a significant growth in short interest during the month of March. As of March 15th, there was short interest totalling 55,700 shares, a growth of 98.2% from the February 29th total of 28,100 shares. Based on an average trading volume of 41,800 shares, the short-interest ratio is presently 1.3 days.
Institutional Trading of ProShares Ultra Nasdaq Biotechnology
Several hedge funds have recently modified their holdings of the company. IMC Chicago LLC purchased a new stake in shares of ProShares Ultra Nasdaq Biotechnology during the fourth quarter valued at about $2,435,000. Jane Street Group LLC purchased a new stake in shares of ProShares Ultra Nasdaq Biotechnology during the fourth quarter valued at about $829,000. Toth Financial Advisory Corp lifted its position in shares of ProShares Ultra Nasdaq Biotechnology by 17.3% during the fourth quarter. Toth Financial Advisory Corp now owns 11,241 shares of the exchange traded fund’s stock valued at $641,000 after buying an additional 1,655 shares during the last quarter. Tower Research Capital LLC TRC lifted its position in shares of ProShares Ultra Nasdaq Biotechnology by 523.9% during the third quarter. Tower Research Capital LLC TRC now owns 6,457 shares of the exchange traded fund’s stock valued at $310,000 after buying an additional 5,422 shares during the last quarter. Finally, Walleye Capital LLC purchased a new stake in shares of ProShares Ultra Nasdaq Biotechnology during the first quarter valued at about $275,000.
ProShares Ultra Nasdaq Biotechnology Stock Down 0.9 %
ProShares Ultra Nasdaq Biotechnology stock traded down $0.55 during midday trading on Thursday, hitting $57.54. 34,738 shares of the company’s stock were exchanged, compared to its average volume of 43,182. ProShares Ultra Nasdaq Biotechnology has a 12 month low of $40.10 and a 12 month high of $62.45. The firm has a 50-day moving average of $57.70 and a two-hundred day moving average of $52.10.
ProShares Ultra Nasdaq Biotechnology Announces Dividend
ProShares Ultra Nasdaq Biotechnology Company Profile
ProShares Ultra Nasdaq Biotechnology (the Fund) seeks daily investment results, before fees and expenses, that correspond to twice (200%) the daily performance of the Index. The return of the Fund for a period longer than a single trading day will be the result of each day’s returns compounded over the period, which will very likely differ from the inverse of the return of the Dow Jones United States Basic Materials Index (the Index) for that period.
See Also
- Five stocks we like better than ProShares Ultra Nasdaq Biotechnology
- What is Insider Trading? What You Can Learn from Insider Trading
- 3 Value Stocks Too Small For Buffett’s Portfolio
- Investing in large cap stocks: Diving into big caps
- Foot Locker Builds Up Another Head of Steam; Gains Imminent
- What is Forex and How Does it Work?
- Disney Stock Catches 3 Upgrades In a Single Week
Receive News & Ratings for ProShares Ultra Nasdaq Biotechnology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ProShares Ultra Nasdaq Biotechnology and related companies with MarketBeat.com's FREE daily email newsletter.